Latest From Mallinckrodt PLC
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.
Biopharma’s funding support for the Institute for Clinical and Economic Review has been slightly above that of payers and providers for the past three to four years.
Nektar's novel opioid oxycodegol will be the first opioid analgesic taken up by an advisory committee in more than a year after the agency spent 2019 reevaluating its regulatory paradigm.
- Medical Devices
- Generic Drugs
- Specialty Pharmaceuticals
- Therapeutic Areas
- Immune Disorders
- Metabolic Disorders
- Neurology, Nervous System
- Renal System
- Respiratory, Pulmonary
- Mallinckrodt LLC
- Mallinckrodt Inc.
- Mallinckrodt Group, Inc.
- Mallinckrodt Pharmaceuticals
- Western Europe
- Parent & Subsidiaries
- Mallinckrodt PLC
- Senior Management
Mark Trudeau, Pres. & CEO
George Kegler, EVP and CFO, Interim
Steven Romano, MD, EVP, CSO
Matthew Harbaugh, President, Specialty Generics
Hugh O'Neill, EVP and Chief Commercial Officer
Dagmar Rosa-Bjorkeson, Chief Strategy and Corp Dev Officer
Frank Scholz, PhD, EVO and Chief Operations/Digital Innovation
- Contact Info
Phone: 17 8463 6700
3 Lotus Park
Staines-Upon-Thames, MO TW18 3AG
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.